Researchers Shared Findings on Novel Markers at the American College of Gastroenterology's 2019 Annual Scientific Meeting in San Antonio
Data from BLUE-C Prospective Study is Expected to Support FDA PMA Submission
MADISON, Wis., Oct. 29, 2019 /PRNewswire/ -- (EXAS) – Promising research from Exact Sciences Corp. and Mayo Clinic shows new methylation and protein markers detect colorectal cancer and advanced adenomas with high accuracy. Findings from the blinded, case-control study were presented at the American College of Gastroenterology's (ACG) 2019 Annual Scientific Meeting today. The study is part of an effort to increase specificity of Cologuard®, while maintaining its high level of sensitivity. Working in collaboration with Mayo Clinic, Exact Sciences has identified novel markers and improved laboratory processes to help achieve its performance enhancement goals and has initiated a 10,000-patient prospective study to validate the performance of the enhanced test.
The new markers were tested alongside the current Cologuard markers on 725 stool samples, including 117 colorectal cancers (CRC), 120 advanced adenomas (AA), 161 non-advanced adenomas (non-AA), and 327 controls. Results showed 92% CRC sensitivity and 65% AA sensitivity at 92% specificity for the new markers. In this study, the new markers exceeded the specificity and sensitivity of the markers currently used in Cologuard.
Current markers* 87%
Re-weighted AA sensitivity**
*Cologuard performance was established in DeeP-C, a prospective study of 10,000 average-risk, asymptomatic patients. The data displayed in this table show performance in a smaller case-control study of 725 samples.
**AA sensitivity re-weighted to match distribution by size of adenoma found in DeeP-C. AA sensitivity is expected to be lower in a prospective study.
"The data presented at ACG are promising," said Kevin Conroy, chairman and CEO of Exact Sciences. "This new study demonstrates the potential to make Cologuard, an accurate, convenient screening option, even better for patients and gives us confidence to move forward with a prospective study. We look forward to generating additional evidence, making an enhanced test available to patients, and solidifying Exact Sciences as the leader in the early, accurate detection of colorectal cancer."
To establish the sensitivity and specificity of the novel multi-target stool DNA test, Exact Sciences recently launched the BLUE-C study, a multi-center, prospective study, with the first patient expected to enroll this November. More than 10,000 patients 40 years of age and older and scheduled for a CRC screening colonoscopy will be enrolled. Patients will collect a stool sample and perform a commercially available fecal immunochemical test (FIT) prior to screening colonoscopy. Patients will be invited to provide a blood sample that Exact Sciences intends to use for validation of a potential blood-based screening test for CRC. Collecting stool and blood in one study is expected to provide significant cost and timing efficiencies.
Screening for CRC can help save lives by preventing the disease or detecting it early.1 Tests that can help accurately detect AAs and early-stage CRC provide the best chance of preventing or treating the disease before it progresses. CRC invades more layers of the colon wall and the blood supply as it advances, making it difficult for blood-based tests to accurately detect early-stage disease.2 Even with this biological limitation, blood-based tests could provide another option to get more people screened.
"While further studies will establish the clinical performance of these new markers, we are encouraged by the strong results presented today," said Paul Limburg, MD, MPH, AGAF, chief medical officer of Exact Sciences and gastroenterologist at Mayo Clinic. "The discovery of these markers by the Exact Sciences and Mayo Clinic teams is fueled by our spirit to continuously improve and advance the fight against this deadly disease."
About the BLUE-C study
The primary objective of this multi-center, prospective study is to determine the sensitivity and specificity of a novel multi-target stool DNA (mt-sDNA) screening test for CRC, using colonoscopy as the reference method. Lesions will be confirmed as malignant by histopathologic examination. Patients 40 years of age and older who are scheduled for a CRC screening colonoscopy will be eligible to participate. After providing written consent to participate in the study and before a screening colonoscopy, subjects will be provided with a stool collection kit and will collect a stool sample for the mt-sDNA screening test and for a commercially available FIT test. Subjects will undergo colonoscopy within approximately 60 days of enrollment. Subjects and clinicians will remain blinded to the results of the mt-sDNA CRC screening test and the FIT test, which will not be used in clinical management. Enrolled subjects will have the option to enroll in a blood collection sub-study for the development of a potential blood-based screening test for CRC.
Mayo Clinic and Dr. Limburg have a financial interest in Exact Sciences.
Megan Jones, email@example.com, 608-535-8815
Stephanie Spanos, firstname.lastname@example.org, 608-556-4380
 Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Colorectal cancer screening: health impact and cost effectiveness. Am J Prev Med 2006; 31:80-9.
 Diehl F et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci 2005; 102(45):16368-16373.
About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences or find Exact Sciences on Facebook.
Cologuard was approved by the FDA in August 2014, and results from Exact Sciences' prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the American Cancer Society's (2018) colorectal cancer screening guidelines and the recommendations of the U.S. Preventive Services Task Force (2016) and National Comprehensive Cancer Network (2016). Cologuard is indicated to screen adults 45 years of age and older who are at average risk for colorectal cancer by detecting certain DNA markers and blood in the stool. Do not use Cologuard if you have had precancer, have inflammatory bowel disease and certain hereditary syndromes, or have a personal or family history of colorectal cancer. Cologuard is not a replacement for colonoscopy in high risk patients. Cologuard performance in adults ages 45-49 is estimated based on a large clinical study of patients 50 and older. Cologuard performance in repeat testing has not been evaluated.
The Cologuard test result should be interpreted with caution. A positive test result does not confirm the presence of cancer. Patients with a positive test result should be referred for diagnostic colonoscopy. A negative test result does not confirm the absence of cancer. Patients with a negative test result should discuss with their doctor when they need to be tested again. False positives and false negative results can occur. In a clinical study, 13% of people without cancer or precancer received a positive result (false positive) and 8% of people with cancer received a negative result (false negative).
Medicare and most major insurers cover Cologuard. For more information about Cologuard, visit www.cologuardtest.com. Rx Only.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payer reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our ability to effectively utilize strategic partnerships, such as our Promotion Agreement with Pfizer, Inc., and acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
View original content to download multimedia:http://www.prnewswire.com/news-releases/exact-sciences-presents-new-stool-based-colorectal-cancer-screening-performance-data-initiates-prospective-screening-study-300947581.html